Cargando…

Autoimmunity/inflammation in a monogenic primary immunodeficiency cohort

Primary immunodeficiencies (PIDs) are rare inborn errors of immunity that have a heterogeneous phenotype that can include severe susceptibility to life-threatening infections from multiple pathogens, unique sensitivity to a single pathogen, autoimmune/inflammatory (AI/I) disease, allergies and/or ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Rae, William, Ward, Daniel, Mattocks, Christopher J, Gao, Yifang, Pengelly, Reuben J, Patel, Sanjay V, Ennis, Sarah, Faust, Saul N, Williams, Anthony P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628267/
https://www.ncbi.nlm.nih.gov/pubmed/28983403
http://dx.doi.org/10.1038/cti.2017.38
_version_ 1783268846601240576
author Rae, William
Ward, Daniel
Mattocks, Christopher J
Gao, Yifang
Pengelly, Reuben J
Patel, Sanjay V
Ennis, Sarah
Faust, Saul N
Williams, Anthony P
author_facet Rae, William
Ward, Daniel
Mattocks, Christopher J
Gao, Yifang
Pengelly, Reuben J
Patel, Sanjay V
Ennis, Sarah
Faust, Saul N
Williams, Anthony P
author_sort Rae, William
collection PubMed
description Primary immunodeficiencies (PIDs) are rare inborn errors of immunity that have a heterogeneous phenotype that can include severe susceptibility to life-threatening infections from multiple pathogens, unique sensitivity to a single pathogen, autoimmune/inflammatory (AI/I) disease, allergies and/or malignancy. We present a diverse cohort of monogenic PID patients with and without AI/I diseases who underwent clinical, genetic and immunological phenotyping. Novel pathogenic variants were identified in IKBKG, CTLA4, NFKB1, GATA2, CD40LG and TAZ as well as previously reported pathogenic variants in STAT3, PIK3CD, STAT1, NFKB2 and STXBP2. AI/I manifestations were frequently encountered in PIDs, including at presentation. Autoimmunity/inflammation was multisystem in those effected, and regulatory T cell (Treg) percentages were significantly decreased compared with those without AI/I manifestations. Prednisolone was used as the first-line immunosuppressive agent in all cases, however steroid monotherapy failed long-term control of autoimmunity/inflammation in the majority of cases and additional immunosuppression was required. Patients with multisystem autoimmunity/inflammation should be investigated for an underlying PID, and in those with PID early assessment of Tregs may help to assess the risk of autoimmunity/inflammation.
format Online
Article
Text
id pubmed-5628267
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-56282672017-10-05 Autoimmunity/inflammation in a monogenic primary immunodeficiency cohort Rae, William Ward, Daniel Mattocks, Christopher J Gao, Yifang Pengelly, Reuben J Patel, Sanjay V Ennis, Sarah Faust, Saul N Williams, Anthony P Clin Transl Immunology Original Article Primary immunodeficiencies (PIDs) are rare inborn errors of immunity that have a heterogeneous phenotype that can include severe susceptibility to life-threatening infections from multiple pathogens, unique sensitivity to a single pathogen, autoimmune/inflammatory (AI/I) disease, allergies and/or malignancy. We present a diverse cohort of monogenic PID patients with and without AI/I diseases who underwent clinical, genetic and immunological phenotyping. Novel pathogenic variants were identified in IKBKG, CTLA4, NFKB1, GATA2, CD40LG and TAZ as well as previously reported pathogenic variants in STAT3, PIK3CD, STAT1, NFKB2 and STXBP2. AI/I manifestations were frequently encountered in PIDs, including at presentation. Autoimmunity/inflammation was multisystem in those effected, and regulatory T cell (Treg) percentages were significantly decreased compared with those without AI/I manifestations. Prednisolone was used as the first-line immunosuppressive agent in all cases, however steroid monotherapy failed long-term control of autoimmunity/inflammation in the majority of cases and additional immunosuppression was required. Patients with multisystem autoimmunity/inflammation should be investigated for an underlying PID, and in those with PID early assessment of Tregs may help to assess the risk of autoimmunity/inflammation. Nature Publishing Group 2017-09-15 /pmc/articles/PMC5628267/ /pubmed/28983403 http://dx.doi.org/10.1038/cti.2017.38 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Original Article
Rae, William
Ward, Daniel
Mattocks, Christopher J
Gao, Yifang
Pengelly, Reuben J
Patel, Sanjay V
Ennis, Sarah
Faust, Saul N
Williams, Anthony P
Autoimmunity/inflammation in a monogenic primary immunodeficiency cohort
title Autoimmunity/inflammation in a monogenic primary immunodeficiency cohort
title_full Autoimmunity/inflammation in a monogenic primary immunodeficiency cohort
title_fullStr Autoimmunity/inflammation in a monogenic primary immunodeficiency cohort
title_full_unstemmed Autoimmunity/inflammation in a monogenic primary immunodeficiency cohort
title_short Autoimmunity/inflammation in a monogenic primary immunodeficiency cohort
title_sort autoimmunity/inflammation in a monogenic primary immunodeficiency cohort
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628267/
https://www.ncbi.nlm.nih.gov/pubmed/28983403
http://dx.doi.org/10.1038/cti.2017.38
work_keys_str_mv AT raewilliam autoimmunityinflammationinamonogenicprimaryimmunodeficiencycohort
AT warddaniel autoimmunityinflammationinamonogenicprimaryimmunodeficiencycohort
AT mattockschristopherj autoimmunityinflammationinamonogenicprimaryimmunodeficiencycohort
AT gaoyifang autoimmunityinflammationinamonogenicprimaryimmunodeficiencycohort
AT pengellyreubenj autoimmunityinflammationinamonogenicprimaryimmunodeficiencycohort
AT patelsanjayv autoimmunityinflammationinamonogenicprimaryimmunodeficiencycohort
AT ennissarah autoimmunityinflammationinamonogenicprimaryimmunodeficiencycohort
AT faustsauln autoimmunityinflammationinamonogenicprimaryimmunodeficiencycohort
AT williamsanthonyp autoimmunityinflammationinamonogenicprimaryimmunodeficiencycohort